Edition:
United States

BioCryst Pharmaceuticals Inc (BCRX.OQ)

BCRX.OQ on NASDAQ Stock Exchange Global Select Market

4.90USD
23 Apr 2018
Change (% chg)

$-0.01 (-0.20%)
Prev Close
$4.91
Open
$4.95
Day's High
$4.95
Day's Low
$4.80
Volume
102,698
Avg. Vol
298,362
52-wk High
$7.39
52-wk Low
$3.95

Select another date:

Tue, Apr 10 2018

BRIEF-Idera Pharma Files Definitive Proxy Statement Over With Pending Merger With Biocryst

* IDERA PHARMACEUTICALS FILES DEFINITIVE PROXY STATEMENT IN CONNECTION WITH PENDING MERGER WITH BIOCRYST PHARMACEUTICALS

BRIEF-RA Capital Management Opposes BioCryst Pharmaceuticals' Proposed Merger With Idera Pharmaceuticals

* RA CAPITAL MANAGEMENT OPPOSES BIOCRYST PHARMACEUTICALS' PROPOSED MERGER WITH IDERA PHARMACEUTICALS

BRIEF-Biocryst Pharmaceuticals Files Definitive Proxy Statement Related To Pending Merger With Idera Pharmaceuticals

* BIOCRYST PHARMACEUTICALS FILES DEFINITIVE PROXY STATEMENT IN CONNECTION WITH PENDING MERGER WITH IDERA PHARMACEUTICALS

BRIEF-Biocryst Announces Initiation Of The Phase 3 Apex-2 Trial Of BCX7353 In Patients With Hereditary Angioedema

* BIOCRYST ANNOUNCES INITIATION OF THE PHASE 3 APEX-2 TRIAL OF BCX7353 IN PATIENTS WITH HEREDITARY ANGIOEDEMA

BRIEF-Biocryst Reports Q4 Loss Per Share of $0.20

* BIOCRYST REPORTS FOURTH QUARTER AND FULL YEAR 2017 FINANCIAL RESULTS

BRIEF-Great Point Partners Opposes Biocryst Pharma Proposed Merger With Idera Pharma

* GREAT POINT PARTNERS LLC OPPOSES THE BIOCRYST PHARMACEUTICAL PROPOSED MERGER WITH IDERA PHARMACEUTICALS, INC.

BRIEF-Great Point Reports 7.60 Pct Stake In BioCryst Pharmaceuticals

* GREAT POINT PARTNERS, LLC REPORTS 7.60 PERCENT STAKE IN BIOCRYST PHARMACEUTICALS INC AS OF FEBRUARY 6, 2018 - SEC FILING‍​ Source text: (http://bit.ly/2HjJO7H) Further company coverage:

BRIEF-Biocryst Pharma And Idera Pharma Sign Merger Agreement To Form New Company

* BIOCRYST PHARMACEUTICALS AND IDERA PHARMACEUTICALS ANNOUNCE MERGER TO COMBINE CAPABILITIES TO SERVE MORE PATIENTS WITH RARE DISEASES

BRIEF-Biocryst Advancing Potential Treatment For Rare And Severely Debilitating Fibrodysplasia Ossificans Progressiva

* BIOCRYST ADVANCING POTENTIAL TREATMENT FOR RARE AND SEVERELY DEBILITATING FIBRODYSPLASIA OSSIFICANS PROGRESSIVA

Select another date: